Apellis Pharmaceuticals Inc (APLS)

Great Lakes Advisors LLC Invests $12.46 Million in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) - MarketBeat

MarketBeat

BNP Paribas Financial Markets Lowers Position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) - MarketBeat

MarketBeat

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Forecasted to Post Q2 2024 Earnings of ($0.41) Per Share - MarketBeat

MarketBeat

M&T Bank Corp Acquires New Position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) - Defense World

Defense World

BNP Paribas Financial Markets Trims Position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) - Defense World

Defense World

Charles Schwab Investment Management Inc. Purchases 25052 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ ... - Defense World

Defense World

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) to Post Q2 2025 Earnings of $0.04 Per Share, Wedbush Forecasts - Defense World

Defense World

Apellis Pharmaceuticals Sees Unusually High Options Volume (NASDAQ:APLS) - Defense World

Defense World

Investors Purchase High Volume of Apellis Pharmaceuticals Call Options (NASDAQ:APLS) - MarketBeat

MarketBeat

Equities Analysts Offer Predictions for Apellis Pharmaceuticals, Inc.'s Q2 2025 Earnings (NASDAQ:APLS) - MarketBeat

MarketBeat

Investigation Alert: Cummins, Apellis Pharmaceuticals, Inspire Medical, and Applied Digital - Johnson Fistel, LLP ... - GlobeNewswire

GlobeNewswire

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Short Interest Update - Defense World

Defense World

Amalgamated Bank Trims Position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) - Defense World

Defense World

Apellis Pharmaceuticals secures $475M credit, maintains Buy rating - Investing.com South Africa

Investing.com South Africa

Apellis Pharmaceuticals secures $475M credit, maintains Buy rating - Investing.com Canada

Investing.com Canada

Short Interest in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Increases By 16.1% - MarketBeat

MarketBeat

Apellis Pharmaceuticals (NASDAQ:APLS) Trading Down 4% - MarketBeat

MarketBeat

Apellis secures $375 million credit facility with Sixth Street - Investing.com South Africa

Investing.com South Africa

Apellis Pharmaceuticals Strives For Recovery Despite Syfovre Setbacks (NASDAQ:APLS) - Seeking Alpha

Seeking Alpha

HC Wainwright Comments on Apellis Pharmaceuticals, Inc.'s Q2 2024 Earnings (NASDAQ:APLS) - MarketBeat

MarketBeat

Swiss National Bank Lowers Stock Position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) - Defense World

Defense World

Q2 2024 Earnings Estimate for Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Issued By HC Wainwright - Defense World

Defense World

Apellis Pharmaceuticals Reports First Quarter 2024 Financial Results - br.ADVFN.com

br.ADVFN.com

HC Wainwright Weighs in on Apellis Pharmaceuticals, Inc.'s FY2025 Earnings (NASDAQ:APLS) - Defense World

Defense World

Despite currently being unprofitable, Apellis Pharmaceuticals (NASDAQ:APLS) has delivered a 164% return to ... - Yahoo Canada Shine On

Yahoo Canada Shine On

Insider Selling: Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Insider Sells 78907 Shares of Stock - Defense World

Defense World

One to Watch Companies - USA, Carvykti, Apellis Pharmaceuticals - The Pharma Letter

The Pharma Letter

Q2 2024 EPS Estimates for Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Raised by Analyst - Defense World

Defense World

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat

MarketBeat

FY2025 Earnings Estimate for Apellis Pharmaceuticals, Inc. Issued By HC Wainwright (NASDAQ:APLS) - MarketBeat

MarketBeat

Apellis Pharmaceuticals, Inc. (APLS) Reports Q2 Loss, Misses Revenue Estimates - Yahoo Movies UK

Yahoo Movies UK

Apellis (APLS) Kindles Acquisition Interest Per Bloomberg - Yahoo News Australia

Yahoo News Australia

Apellis Pharmaceuticals, Inc. to Post FY2026 Earnings of $4.29 Per Share, Wedbush Forecasts (NASDAQ:APLS) - Defense World

Defense World

UBS Group Trims Apellis Pharmaceuticals (NASDAQ:APLS) Target Price to $85.00 - Defense World

Defense World

Apellis Pharmaceuticals (NASDAQ:APLS) Receives Buy Rating from HC Wainwright - Defense World

Defense World

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Receives Average Recommendation of “Moderate Buy” from Analysts - Defense World

Defense World

Needham & Company LLC Reiterates “Buy” Rating for Apellis Pharmaceuticals (NASDAQ:APLS) - Defense World

Defense World

Apellis Pharmaceuticals executive sells over $3.3 million in stock - Investing.com India

Investing.com India

Apellis Pharmaceuticals executive sells over $3.3 million in stock - Investing.com

Investing.com

Wedbush Weighs in on Apellis Pharmaceuticals, Inc.'s FY2026 Earnings (NASDAQ:APLS) - MarketBeat

MarketBeat

Analysts Are Updating Their Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Estimates After Its First-Quarter Results - Yahoo Finance

Yahoo Finance

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) First-Quarter Results: Here's What Analysts Are Forecasting For This Year - Simply Wall St

Simply Wall St

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) First-Quarter Results: Here's What Analysts Are Forecasting For This Year - Simply Wall St

Simply Wall St

Apellis stock sell-off over Syfovre sales "overdone," says Citi - MSN

MSN

In-Depth Examination Of 14 Analyst Recommendations For Apellis Pharmaceuticals

Benzinga

Apellis stock sell-off over Syfovre sales "overdone," says Citi (NASDAQ:APLS) - Seeking Alpha

Seeking Alpha

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Q1 2024 Earnings Call Transcript - Insider Monkey

Insider Monkey

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Q1 2024 Earnings Call Transcript - Yahoo Finance

Yahoo Finance

Apellis Pharmaceuticals Inc (APLS) Q1 2024 Earnings Call Transcript Highlights: Robust Revenue Growth and ... - GuruFocus.com

GuruFocus.com

Apellis Pharmaceuticals First Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance

Yahoo Finance